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Nicholas G. Smedira, MDLietz and colleagues1 examined neurologic dysfunction
after placement of left ventricular assist device (LVAD),
an important and timely topic. Almost as important is the
fact that the LVAD examined, the HeartMate XVE (Thora-
tec, Pleasanton, Calif), a first-generation displacement
pump, will soon be of historical interest only with the suc-
cessful use of continuous flow pumps. The value of this
work as I saw it was to heighten our awareness of how
limited our understanding of cerebral and organ perfusion
during mechanical support is—whether it be too much, too
little, or the wrong type—and to encourage us to intensify
our investigations into understanding this in an effort to im-
prove patient management and reduce complications.
Since the approval of the HeartMate II for bridge to
transplantation in April 2008 and the use in clinical trials
of third-generation centrifugal pumps such as the Duraheart
(Terumo Heart, Ann Arbor, Mich), Heartware (Heartware
International, Framingham,Mass), and VentrAssist (Ventra-
cor, Foster City, Calif) pumps, continuous flow pumps have
become the devices of choice at almost all major institutions,
and rightfully so. Bridge-to-transplant success is greater than
70%, with outstanding device reliability and durability,
a threefold reduction in reoperations for bleeding, and
a phenomenal 10-fold reduction in driveline infections.2
Concerns about inadequate flow in larger patients, inducing
right ventricular failure and persistence of pulmonary hyper-
tension, have been shown to be unfounded. As a result,
patients and their physicians are beginning to consider
mechanical circulatory support with these pumps as a worth-
while alternative for the treatment of heart failure.
What has emerged as new, vexing complications, too fre-
quent and devastating to ignore, are gastrointestinal (GI) and
intracerebral bleeding (ICB). Crow and colleagues3 have re-
ported that GI bleeding is 10 times more frequent in patients
supported with a variety of continuous flow pumps when
compared with pulsatile pumps, and this rate of bleeding
is much higher than seen in patients with mechanical valves
and similar levels of anticoagulation. Overall, neurologic
events were low in the HeartMate II trial (with the exception
of women, for whom the stroke rate was 18%), but 3% of
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doi:10.1016/j.jtcvs.2009.03.048The Journal of Thoracic andpatients had ICB, and in our past 50 cases, 5 patients had
ICB (1 traumatic). ICB has been reported with all continuous
flow pumps.4,5 Why is this?
Surprisingly, there are very few data on the cerebral blood
flow response to long-term nonpulsatile flow.6 The unsub-
stantiated hypothesis purposed to explain GI bleeding is
that similar to reduced pulsatility aortic stenosis, arterial–ve-
nous malformations form or are unmasked, leading to bleed-
ing, especially in the setting of dual-agent anticoagulation. I
could not find evidence to support this occurrence in the
brain. Another theory is that the high sheer stress of contin-
uous flow pumps results in an acquired von Willebrand fac-
tor deficiency, and this along with anticoagulation increases
the risk of hemorrhagic complications.7,8 Small series have
been inconsistent, and it is not clear how important this is.
Device anticoagulation regimens have been modeled on
therapy for prosthetic valve replacement, which may or
may not be appropriate or even necessary, and the tests
used to monitor levels of anticoagulation have been
relatively crude and inexact. We are just beginning to under-
stand how the patient’s illness, immune response (heparin-
induced thrombocytopenia, for example), and mechanical
properties of the pump alter the hemostatic milieu and
what tests (platelet aggregation assays, thromboelastogra-
phy, factor levels, and von Willebrand assays) are most
useful in directing therapeutic interventions. We have also
not considered that the requirement for and level of antico-
agulation may change over time.
Hypertension is a risk factor for ICB. We are now discus-
sing how to define normal blood pressure when there is little
or no pulsatility. What does a radial artery Doppler-derived
sound at 100 mm Hg cuff pressure mean? It is not a mean
blood pressure, as there is no diastole, and diastole or a de-
clining blood pressure occupies two-thirds of the cardiac
cycle. This would suggest that a continuous, never-varying
blood pressure of 90 to 100 or more is extremely high. Lietz
and colleagues1 have pointed out that baseline cerebral
blood flow is reduced up to 30% in patients with advanced
heart failure, and our therapeutic management often reduces
systemic blood pressure to enhance cardiac output. Could
normalizing blood pressure after support from a low baseline
during heart failure increase the risk of ICB?
It is important to note that the patients of Lietz and col-
leagues1 did not have evidence of ICB, and that has been
our experience with pulsatile pumps—even with the Nova-
cor LVAD (World Heart, Oakland, Calif), which initially
had extremely high stroke rates with intensive anticoagula-
tion. Hyperperfusion neurologic dysfunction was correlatedCardiovascular Surgery c Volume 138, Number 1 9
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Editorials Smedirawith higher flows but not hypertension. What flow rates,
what level of blood pressure, and what degree of pulsatility,
if any, are optimal for organ perfusion remain unknown.
Over the past decade, improvements in patient manage-
ment and selection, and most importantly device design,
have made mechanical support for both bridge and perma-
nent therapy a safe, reliable, and realistic option for many
more patients with heart failure. Improving our understand-
ing of device–patient interaction will go a long way toward
reducing complications and improving the patient’s quality
of life. Lietz and colleagues’ work1 may already be outdated,
but the idea of understanding the complex interplay of
device flow characteristics and organ physiology is more
important than ever.
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